Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pregnancy-specific beta-1-glycoprotein 7 (PSG7) is a member of the pregnancy-specific glycoprotein family, itself part of the carcinoembryonic antigen (CEA) gene family within the immunoglobulin superfamily. PSG7 is predominantly expressed by placental trophoblasts and released into the maternal circulation during pregnancy; its primary proposed role is supporting the maintenance of a normal pregnancy, likely through immunomodulatory functions at the maternal-fetal interface. Clinical associations include gestational trophoblastic neoplasms and certain pregnancy complications, and PSG7, like other PSG proteins, may be relevant as a biomarker for placental function. However, PSG7 is not known to be a direct therapeutic target, nor is it a canonical receptor, enzyme, or transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pregnancy-specific beta-1-glycoprotein 7 (PSG7).